efferon-lps-2023-01
Проводит Efferon JSC
Страница компанииA Multicenter Prospective Observational Study With a Control Group to Evaluate the Efficacy and Safety of LPS Adsorption Using the Efferon LPS NEO Device in Children With SepSis (LASSO NEO).
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT05707494/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование завершено, новых участников не набирают.
- Возраст участников: 1 мес. — 14 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 78 чел. во всех странах исследования.
- Центров в реестре: 7 в 2 городах. Список — ниже на странице.
- Плановая дата окончания (04.2025) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 7 · невключение: 10
Критерии включения
- Weight from 5 kg. up to 40 kg (main criterion),
- Age from 1 month to 14 years,
- No more than 12 hours from the moment of establishment of DZ - Sepsis in accordance with the criteria of SEPSIS-3 (2016, modified for childhood), most likely, Gr-etiology, at the time of inclusion.
- The immediate postoperative period in case of abdominal nature of sepsis (no more than 12 hours after surgery),
- If the patient has a focus of surgical infection, then it should be sanitized,
- pSOFA scale ≥ 6 points, or an increase in negative dynamics on the pSOFA scale by 2 or more points over 12 hours of observation,
- The patient's condition allows for therapy with the Efferon LPS NEO column for at least 4 hours.
Критерии невключения
- Weight below 5 kg and over 40 kg,
- Age less than 1 month and over 14 years old,
- Failure to obtain informed consent from the patient's parents, family member or legal representative,
- The presence of a focus of non-sanitized surgical infection,
- Use in the treatment of other methods of extracorporeal removal of LPS and inflammatory mediators (hemofilters with highly permeable and surface-modified membranes),
- Acute pulmonary embolism,
- Intracranial hemorrhage or bleeding tendency in general,
- Induced aplasia of hematopoiesis,
- If it is impossible to provide vascular access necessary for the method,
- Any other condition that, in the opinion of the Investigator, would prevent the patient from being a suitable candidate for inclusion in the trial (for example, a chronic disease in the terminal stage or a mental disorder that affects the methodology for conducting a hemoperfusion procedure, as well as for patients who have a "palliative status ").
Источник: ClinicalTrials.gov, NCT05707494 · запись обновлена в реестре 5 июня 2025.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 5
- Effect of Efferon LPS NEO Hemoperfusion on pSOFA (pediatric Sequential Organ Failure Assessment) Scores in Patients with Sepsis — 1-7 days
Цель исследования
One of the major health problems in the world is sepsis, the number of cases of which, according to WHO, annually reaches 20-30 million. The decrease in the sensitivity of bacterial pathogens to antibiotics, the widespread use of invasive diagnostic and treatment methods, the increased role of opportunistic microorganisms and fungi, and the increase in the number of people with severe chronic diseases led to an increase in the incidence of sepsis in the period from 1979 to 1979. 2000 by 8.7% per annum.
Sepsis is one of the leading causes of hospital mortality in children. Multicenter cross-country studies of pediatric sepsis using a prospective methodology in nearly 7,000 children (mean age 3 years) in 128 pediatric intensive care units (ICUs) in 26 different countries showed that a typical 16-bed intensive care unit should have, on average, at least one child with sepsis.
Sepsis and septic shock in most cases are accompanied by the development of multiple organ failure syndrome (MODS). The frequency of adverse outcomes directly depends on the number of organ systems involved in MODS: it increases from 6% in patients with dysfunction of one organ at the time of admission to the intensive care unit to 65% in patients with organ failure of 4 systems or more. Despite modern advances in resuscitation and antimicrobial chemotherapy, if the etiological agent of sepsis is gram-negative flora, mortality can reach 75%.
Numerous studies have shown that the use of extracorporeal sorption methods that eliminate endotoxin improves the results of treatment of patients with septic shock. The use of LPS selective adsorption is both an etiological and pathogenetic method of treatment, which justifies the need for its use in the complex intensive care of sepsis and septic shock.
The method of hemosorption technology using a cartridge based on a mesoporous supercrosslinked copolymer of styrenedivinylbenzene with an LPS-selective ligand immobilized on the surface, which has the ability to neutralize the biological activity of endotoxin by binding lipid A, the main pathogenic site of LPS. the molecule matters.
The main goal of the study was to obtain data on the efficacy and safety of using the Efferon LPS NEO hemosorption column for the adsorption of lipopolysaccharides during extracorporeal detoxification in children aged 1 month to 14 years with sepsis.
Где проходит
7 центров в 2 городах- Children's City Clinical Hospital named after St. Vladimir of the Moscow Department of Health
- Clinical and Research Institute of Emergency Pediatric Surgery and Traumatology
- Filatov Children's City Clinical Hospital of the Moscow Health Department
- ГБУЗ города Москвы «Детская городская клиническая больница № 9 им. Г.Н. Сперанского ДЗМ»
- ГБУЗ города Москвы «Морозовская детская городская клиническая больница ДЗМ»
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT05707494 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.